Micron Technologies Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Malvern PA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
None
First Marketed Drug
2019
naproxen (naprosyn)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (2)

cetirizine (zyrtec) (2020)

naproxen (naprosyn) (2019)

Drugs in Phase 4 Trials (1)

Key: Micron Technologies (0) Acquired (1)

pancrelipase (creon) (1 trial)

Drugs in Phase 3 Trials (2)

Key: Micron Technologies (0) Acquired (2)

progesterone (progestasert) (4 trials)

s-adenosyl methionine (1 trial)

Drugs in Phase 2 Trials (1)

Key: Micron Technologies (0) Acquired (1)

lidocaine (xylocaine) (2 trials)

Drugs in Phase 1 Trials (1)

Key: Micron Technologies (0) Acquired (1)

medi1341 (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 9
  • # of Trial APIs: 5